A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab
Crossref DOI link: https://doi.org/10.1136/annrheumdis-2015-208914
Published Online: 2016-07-27
Published Print: 2017-03
Update policy: https://doi.org/10.1136/crossmarkpolicy
Kaur, Primal
Chow, Vincent
Zhang, Nan
Moxness, Michael
Kaliyaperumal, Arunan
Markus, Richard
Funding for this research was provided by:
Amgen